Advertisement


Yasir Y. Elamin, MD, on Brigatinib in ALK-Rearranged Metastatic Non–Small Cell Lung Cancer

IASLC 2023 WCLC

Advertisement

Yasir Y. Elamin, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the BRIGHTSTAR study, in which brigatinib with local consolidative therapy was found to be safe in patients with ALK-rearranged advanced non–small cell lung cancer. This regimen yielded promising outcomes when compared with historical outcomes with brigatinib alone (Abstract OA22.04).



Related Videos

Lung Cancer
Genomics/Genetics

Xiuning Le, MD, PhD, on Update on the Use of Tepotinib to Treat an NSCLC Subset

Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results of the VISION trial, the largest on-treatment liquid biopsy biomarker data set of a MET inhibitor in patients with MET exon 14 non–small cell lung cancer (NSCLC). Tepotinib showed durable efficacy in this population.

Lung Cancer

Chee K. Lee, PhD, MBBS, on Durvalumab, Tremelimumab, and Chemotherapy in NSCLC

Chee K. Lee, PhD, MBBS, of the University of Sydney, discusses findings of the ILLUMINATE study, which showed durvalumab and tremelimumab with chemotherapy yielded antitumor activity in patients with non–small cell lung cancer (NSCLC) whose tumors progressed after receiving EGFR inhibitors. This result was especially marked in those with EGFR T790M–negative tumors (Abstract OA09.04).

Lung Cancer
Genomics/Genetics

Benjamin Besse, MD, PhD, on EGFR-Mutated NSCLC: Update on Patritumab Deruxtecan in Previously Treated Disease

Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, discusses phase II findings from the HERTHENA-Lung01 study, which showed patients with previously treated EGFR-mutated non–small cell lung cancer may benefit from the antibody-drug conjugate patritumab deruxtecan after EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy (Abstract OA05.03). The phase III HERTHENA-Lung02 trial is ongoing.

Lung Cancer

Ticiana A. Leal, MD, on Tumor Treating Fields and Immune Checkpoint Inhibition in Metastatic NSCLC

Ticiana A. Leal, MD, of Winship Cancer Institute at Emory University, discusses phase III findings from the LUNAR study of tumor treating fields (electric fields that disrupt cellular processes and lead to cell death) combined with the standard of care in patients with metastatic non–small cell lung cancer (NSCLC) after relapse on platinum treatment. The survival benefit of this regimen was especially profound in patients with tumor PD-L1 expression who received an immune checkpoint inhibitor as the standard of care, according to Dr. Leal (Abstract OA22.05).

Lung Cancer
Immunotherapy

Shirish M. Gadgeel, MD, on Pembrolizumab Plus Chemotherapy for Metastatic NSCLC: 5-Year Follow-up

Shirish M. Gadgeel, MD, of the Henry Ford Cancer Institute, discusses a 5-year follow-up study of patients with metastatic non–small cell lung cancer (NSCLC) who were treated with pembrolizumab plus chemotherapy. According to Dr. Gadgeel, the findings continue to support the use of pembrolizumab plus chemotherapy as a standard-of-care first-line treatment, including in tumors with a PD-L1 tumor proportion scores of less than 1%.

Advertisement

Advertisement




Advertisement